‘This is the mental health moment’: Innovation and M&A are helping to boost these stocks to new heights
Two recent M&A announcements by big pharma are creating excitement among investors. Here's who is poised to benefit. Source link
Read More
Abbvie Inc
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker
Read More
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read More
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push
Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business.
Read More
Stocks making the biggest moves midday: Macy’s, Cigna Group, Eli Lilly, Paramount and more
These are the stocks posting the largest moves in midday trading. Source link
Read More
Stocks making the biggest moves midday: Advanced Micro Devices, Alphabet, Sprinklr, Chewy and more
These are the stocks posting the largest moves in midday trading. Source link
Read More
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic
Read More
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the
Read More
Will the ‘Magnificent Seven’ have another good run in 2024? Morgan Stanley’s Mike Wilson weighs in
The investment bank's chief U.S. equity strategist says the risk of recession will be higher than normal next year —
Read More